

# Biotechgate Licensing Deals

## Kinase Inhibitors - Sample Deal

Created for:

**Sample**

-  
-

June 11, 2014

Source: [www.biotechgate.com](http://www.biotechgate.com)

---

### Disclaimer

This report has been produced exclusively for the organization mentioned on the frontpage of this report. No part of this report may be reproduced or transmitted in any form or by any means to any third party outside of client's organization. The information in this report has been collected and validated on a best-effort-basis. However, Venture Valuation does not guarantee the completeness or accuracy of any profile published in the database. Venture Valuation cannot be held liable for any information available or missing from the database. Furthermore, the terms of use published on [www.biotechgate.com](http://www.biotechgate.com) are (where feasible) also applicable to this report.

## Biotechgate Kinase Inhibitors - Sample Deal

### Summary table (1 licensing deals)

Year	Licensor	Licensee	Compound details	Indication/Therapeutic area	Development status	No.
2011	Pharmacylics, Inc.	Johnson & Johnson (Janssen Biotech)	Kinase inhibitors - Bruton's tyrosine kinase (Btk) inhibitors	Lymphoid leukaemia	Phase II	# 1
				Non-Hodgkin's lymphoma	Phase II	
				Myeloma	Phase II	

## Pharmacyclics, Inc. Johnson & Johnson (Janssen Biotech)

#1

### General Deal Information

<b>Licensor</b>	Pharmacyclics, Inc. <a href="http://www.pharmacyclics.com">www.pharmacyclics.com</a>	<b>Licensee</b>	Johnson & Johnson (Janssen Biotech) <a href="http://www.jnj.com">www.jnj.com</a>
<b>Year</b>	2011		

### Compound details

<b>Compound name</b>	Ibrutinib (PCI-32765 (Imbruvica(TM)))
<b>Compound details</b>	Kinase inhibitors - Bruton's tyrosine kinase (Btk) inhibitors

### Disease Areas

<b>Disease Area</b>	Neoplasms / cancer / oncology
<b>Indication</b>	Lymphoid leukaemia
<b>Phase</b>	Phase II
<b>Disease Area</b>	Neoplasms / cancer / oncology
<b>Indication</b>	Non-Hodgkin's lymphoma
<b>Phase</b>	Phase II
<b>Disease Area</b>	Neoplasms / cancer / oncology
<b>Indication</b>	Myeloma
<b>Phase</b>	Phase II

### Deal Terms

<b>Upfront amount</b>	USD 150 million
<b>Milestones total amount</b>	USD 825 million
<b>Milestones regulatory amount</b>	USD 825 million
<b>Milestones regulatory remarks</b>	50 upon inclusion 5th patient F II relapsed/refractory mantle cell lymphoma; 50 upon inclusion 5th patient F III relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma; 75 upon NDA filing acceptance for previously treated mantle cell lymphoma, previously treated chronic lymphocytic leukaemia and small lymphocytic lymphoma; in total 350 approval related milestones; 60 upon FDA approval chronic lymphocytic leukaemia
<b>Milestones sales amount</b>	0
<b>Research funding amount</b>	0
<b>Profit sharing licensor</b>	50%
<b>Profit sharing licensee</b>	50%
<b>Royalties amount</b>	0

**Pharmacyclics, Inc.**  
**Johnson & Johnson (Janssen Biotech)**

**#1**

**Equity amount** 0

**Territory** worldwide

**Remarks** Oral; rights to all indications excluding all immune mediated diseases or conditions and all psychiatric or psychological diseases or conditions; includes rights to back-up compounds; cost-sharing Pharmacyclics: Johnson & Johnson = 40:60; co-commercialization Pharmacyclics leading in USA; Johnson & Johnson outside USA; orphan status for all indications; also orphan drug status for Waldenstrom's macroglobulinemia, diffuse large B-cell lymphoma and small lymphocytic lymphoma

---

**Disclaimer**

This report has been produced exclusively for the organization mentioned on the frontpage of this report. No part of this report may be reproduced or transmitted in any form or by any means to any third party outside of client's organization. The information in this report has been collected and validated on a best-effort-basis. However, Venture Valuation does not guarantee the completeness or accuracy of any profile published in the database. Venture Valuation cannot be held liable for any information available or missing from the database. Furthermore, the terms of use published on [www.biotechgate.com](http://www.biotechgate.com) are (where feasible) also applicable to this report.